Expression of human clotting factor Ⅸ mediated by recom- binant lentiviral vector in cultured cells and hemophilia B mice

To explore the expression of human clotting factor Ⅸ (hFⅨ) cDNA in vitro and the feasibility of gene therapy for hemophilia B mice mediated by recombinant lentiviral vector, a recombinant hFⅨ lentiviral vector driven by ubiquitin-C promoter, FUXW, and by ABP liver specific promoter, FAXW, was constructed respectively. Recombinant lentivirus was harvested from 293T cells by calcium phosphate-mediated transient cotransfection of three plasmids (transgene vector, CMV腞8.2, VSV-G). hFⅨ expression was detected in supernatant of 293T, BHK and L-02 cells infected with FUXW virus, whereas higher expression of hFⅨ levels (630 ng/106 cells/48 h) was detected only in L-02 cells infected with FAXW virus. Serum hFⅨ antigen was detected in all hemophilia B mice treated with FAXW virus by tail vein injection, an efficiency level of hFⅨ was observed (45 ng/mL, approximately 1% of normal human levels), the expression lasted for more than 60 d. The results indicated that HIV-based lentiviral vectors offer a promising approach to the gene therapy of hemophilia B.     

Preparation of a recombinant adeno-associated viral vector with a mutation of human factor Ⅸ in large scale and its expression in vitro and in vivo

A series of adeno-associated viral vectors containing a mutation of human factor Ⅸ (hFⅨR338A) with different regulation elements were constructed and used to transduce cell lines. The plasmids and the stable transduction cell clones with high expression level of hFⅨR338A were obtained by selecting and optimizing, and then, the recombinant adeno-associated viral vector with hFⅨR338A was prepared via novel rHSV/AAV hybrid virus packaging system on a large scale, which contained the capsid protein genes. A method for producing rAAV-hFⅨR338A viral stocks on a large scale and higher titer was established, which can be used for industrial purpose. The titer of rAAV-hFⅨR338A was more than 1.25×10¹² particle/mL, and then, a mammalian cell line, C2C12 and the factor Ⅸ knock-out mice were transfected with the rAAV-hFⅨR338A in vitro and in vivo. The results show that the high-level expression of rAAV-hFⅨR338A was achieved in cell line and hemophilia B mice. It reached at (2551.32±92.14) ng·(10⁶ cells)^-1·(24 h)^-1 in C2C12 cell in vitro and had a peak concentration of 463.28 ng/mL in mice treated with rAAV-hFⅨR338A, which was as high as the expression of rAAV-hFⅨ-wt (2565.76±64.36) ng·(10⁶ cells)^-1·(24 h)^-1 in C2C12 and 453.92 ng/mL in the mice treated with rAAV-hFⅨ-wt) in vitro and in vivo, there is no any difference between two groups, but the clotting activity of hFⅨR338A is about 2.46 times higher than that of hFⅨ-wt. It was first reported that a mutation of human factor Ⅸ was used into gene therapy research for hemophilia B, meanwhile, a novel packaging system, rAAV/HSV was used for preparation of rAAV-hFⅨR338A on a large scale, which laid the foundation of industrial production for applying rAAV viral stocks to gene therapy clinical trial for hemophilia B mediated with rAAV-hFⅨ.     

Expression of biologically active human clotting factor Ⅸ(hFⅨ) in the mammary gland of transgenic mice

The DNA of human factor Ⅸ (hFⅨ) gene vector pMCⅨm, which had been proven to be able to express in in vitro and living cells, was introduced into 586 zygotes of Kunming White Mice by positive pressure microinjection technique with manual operation. The 499 survival embryos after microinjection were then transferred into pseudopregnant recipient mice and 216 F 0 pups were born. The analysis of PCR and Southern blot hybridization showed that, of the 216, 6 (2 females and 4 males) were integrated with foreign DNA in their genomes, giving an integration frequency of 3% (6/216). Two F\-0 female transgenic mice could express hFⅨ protein in their milk and the content was over 100 ng/mL as measured with ELISA. The biological activities of hFⅨ in the milk of two F\-0 mice were 44 67% and 79 43%, respectively.     

以蛋黄为对象对细胞增殖过程中卟啉代谢规律的研究

在以鸡胚胎为细胞繁殖模型,对细胞增殖过程中卟啉代谢规律的研究中,为了寻求能够更好的反映原卟啉Ⅸ(PpⅨ)代谢水平的监测对象,采用405 nm的激发波长,分别对鸡胚胎发育进程中的种蛋中的蛋黄、蛋清和尿囊液的荧光光谱进行测量分析。结果表明,和蛋清相比,蛋黄中PpⅨ 的荧光峰相对背景更为明显,在整个鸡胚发育过程中存在的时间也较长,是一种更为理想的对鸡胚胎发育进程中卟啉代谢规律进行研究的监测对象;同时发现在胚胎发育的初级阶段,蛋黄中PpⅨ的代谢水平随着发育的进程而逐渐升高,在第10天左右达到最大值,在发育后期代谢水平又逐渐降低。鸡胚胎发育进程中PpⅨ的这一代谢规律与其在恶性肿瘤发展过程中的代谢规律极为相似,进一步支持了卟啉代谢异常与细胞无限的迅速增殖相关的观点。     

广义相对论中带体积粘滞性的毕安基-Ⅸ型宇宙弦模型

对定域旋转对称的毕安基-Ⅸ型宇宙弦模型进行了研究,讨论了两个模型,第一个模型中引入了一个普遍采用的状态方程ρ=kλ,第二个模型中引入了粘滞系数与体积膨胀系数成正比的条件ξ=hθ.我们对两个模型的物理和几何性质作了讨论,这些模型描述的是一个以大爆炸为开始的连续膨胀的宇宙模型,并把文献中的一些结果作为特例包括在内.     

人体血清中原卟啉Ⅸ自体荧光光谱研究

通过对人体血清样品和模拟人体生理条件下原卟啉Ⅸ和牛血清白蛋白混合溶液的荧光光谱测定和分析,表明人体血清中原卟啉Ⅸ的自体荧光光谱主要来自于原卟啉Ⅸ和血清白蛋白的结合形式。此外,还考察了血清白蛋白和原卟啉Ⅸ对原卟啉Ⅸ荧光发射峰的影响。和不含有白蛋白的原卟啉Ⅸ溶液相比较,白蛋白不但使原卟啉Ⅸ产生的荧光峰发生红移,而且具有很强的增敏效应。在白蛋白存在条件下,当原卟啉Ⅸ浓度值小于0.8×10-5 mol·L-1时,随着它的浓度增加,原卟啉Ⅸ的荧光发射峰稍有红移;而当原卟啉Ⅸ浓度值大于0.8×10-5 mol·L-1时,其荧光发射波长几乎不随原卟啉Ⅸ浓度而变化。